| Grab sources and discover more here: YDES Website. YDES 424B3. -----
5 Potential (Nasdaq: YDES) Catalysts On Our Radar
No. 1: A Very Low Float Could Create A Situation For Significant Volatility Potential.
With roughly 1.42Mn shares in its float, volatility potential could become heightened at the drop of a hat for YDES.
No. 2: Pioneering Clinical Platforms And Strategic Growth Roadmap For 2026 Success.
YD Bio Ltd. achieved major milestones spanning stem cell therapy, exosome innovation, and DNA methylation‑based cancer detection.
With core manufacturing and regulatory frameworks completed, the company is positioned to advance into global clinical and commercial phases.
Its 2026 roadmap emphasizes asset‑level development, accelerated IND filings, and strategic acquisitions to strengthen precision medicine offerings.
These achievements reflect YD Bio’s commitment to scientific rigor, regulatory readiness, and impactful innovation—building momentum toward accelerated value creation, enhanced therapeutic potential, and robust global expansion opportunities through 2027 and beyond.
No. 3: Expanding American Footprint With New California Operations And Facility Plans.
YD Bio Ltd. announced plans for a California operations center to deepen its U.S. presence, accelerate clinical programs, and enhance regulatory collaboration.
The phased expansion will establish new laboratory, manufacturing, and commercial functions, driving faster validation and market access for advanced diagnostics and exosome‑based therapeutics.
This initiative supports long‑term growth, job creation, and broader adoption of non‑invasive testing technologies nationwide.
No. 4: Advancing The OkaiDx™ Platform For Broader Cancer Detection And Research Excellence.
YD Bio Ltd. expanded its OkaiDx™ blood‑based testing portfolio to pancreatic and colorectal cancer detection across 44 U.S. states.
Partnering with EG BioMed, it now integrates nationwide telehealth support and at‑home blood collection services, making early detection more accessible.
Recent clinical data highlight 93.8% sensitivity for early‑stage pancreatic cancer—reinforcing the promise of the platform’s methylation‑based biomarkers.
These advances strengthen YD Bio’s leadership in precision oncology and exemplify its dedication to improving early diagnosis and proactive patient care through smart, scalable innovation.
No. 5: Entering U.S. Ophthalmology Market With Exovisse Innovations And Therapeutic Progress.
YD Bio Ltd. achieved a landmark U.S. entry in ophthalmology with Exovisse Contact Lenses receiving FDA 510(k) clearance and Exovisse Artificial Tears meeting OTC monograph standards.
These milestones enable nationwide distribution and mark YD Bio’s transition from research to real‑world patient solutions.
Alongside ongoing FDA filings for limbal stem cell‑derived therapeutics, the company is building a powerful foundation in eye‑care innovation.
This progress solidifies YD Bio’s role as a growing leader addressing unmet visual health needs while advancing new regenerative treatment platforms globally. -----
Now official: coverage is underway on YD Bio Ltd. (Nasdaq: YDES).
As soon as updates are available, we'll whip them out to you right away.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/05/2026 and ending on 01/06/2026 to publicly disseminate information about (YDES:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (YDES:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ydes-um0ce/#details | 
